Topical haemoglobin spray for chronic wound therapy

Wound oxygenation

- Time to heal diabetic foot ulcers 50% shorter than with standard of care\(^1\)
- Twice as many chronic wounds healed at 8–16 weeks compared to standard of care\(^1,2,3\)
- More than 70% lower average pain scores at four weeks than with standard of care in chronic wounds\(^3\)
- Less slough during wound management: 99% less slough in chronic wounds after 4 weeks compared to 33% with standard of care\(^4\)
- Treatment costs in diabetic foot ulcers at least 40% lower than with standard of care\(^5\)

12 ml unit = 3 months treatment*

*May vary slightly depending on wound size
Complex, stalling and chronic wounds

Chronic wounds

A hard-to-heal wound has been defined as one that fails to heal with ‘standard therapy’ in an orderly and timely manner. Irrespective of this time-based definition, wounds are classified as chronic from the outset, if they require treatment for a persistent underlying cause. This includes, for example, diabetic foot ulcers, wounds associated with peripheral artery disease, venous leg ulcers, or pressure ulcers.

The success of any treatment of chronic wounds hinges on the diagnostic determination and the causal treatment of the underlying, pathophysiologically relevant diseases.

This will include relevant psychosocial factors. In parallel, the majority of patients should receive moist wound therapy based on the various phases of wound healing.

The importance of oxygen in wound healing

Measurement of tissue oxygenation

Increased oxygen requirement, but poor oxygen supply: the need for oxygen is particularly high in all phases of wound healing because of increased metabolic activity. The underlying, primary disease (e.g. diabetes, arterial occlusive disease) leads to inadequate oxygen supply via the impaired vascular system, resulting in hypoxia in the wound area. The lack of oxygen leads to delayed healing, or in some cases even blocks any progression in healing.

Making oxygen available to the wound tissue

A liquid film as thin as 0.02 mm (20 micrometres) blocks 95% of un-aided oxygen diffusion. Despite oxygen being readily available in the ambient air, diffusion to the base of the wound bed is limited by barriers such as wound exudate.

The wound healing process can be facilitated and accelerated by delivering oxygen into the wound bed to combat hypoxia.

‘In the absence of other wound healing inhibitory factors, local hypoxia is the central problem of an impaired wound healing.’

Kröger et al.
The way it works

Unique mode of action – Granulox® acts like a shuttle for oxygen molecules

Granulox® provides the wound with the required oxygen by means of diffusion. The active substance haemoglobin supplies the base of the wound externally with oxygen.

1. From the moment Granulox® is sprayed, the highly purified haemoglobin starts to bind oxygen from the environment. Oxygen loaded haemoglobin diffuses through the wound exudate.

2. Due to the concentration gradient oxygen is released and the haemoglobin molecule is available to bind oxygen again. The reversible oxygen binding property of hemoglobin means each molecule can contribute to multiple cycles of oxygen binding and release.

Granulox® increases wound oxygenation*

1. Before Granulox®:
The majority of the area is blue, indicating low oxygenation.

2. 20 minutes after Granulox®:
Large areas of red and white are clearly recognisable, indicating high oxygenation levels throughout the wound tissue.

The oxygen saturation increases significantly in the tissue below the wound bed after application of Granulox®.

*3D images of the leg ulcer with StO₂.
Clinical efficacy

1) Wound size reduction in DFU

Percent wound size change versus baseline by week

<table>
<thead>
<tr>
<th>Week</th>
<th>Control</th>
<th>Haemoglobin spray</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0%</td>
<td>-26%</td>
</tr>
<tr>
<td>4</td>
<td>-26%</td>
<td>-37%</td>
</tr>
<tr>
<td>8</td>
<td>-37%</td>
<td>-37%</td>
</tr>
<tr>
<td>12</td>
<td>-37%</td>
<td>-37%</td>
</tr>
<tr>
<td>16</td>
<td>-37%</td>
<td>-37%</td>
</tr>
<tr>
<td>20</td>
<td>-37%</td>
<td>-37%</td>
</tr>
<tr>
<td>24</td>
<td>-37%</td>
<td>-37%</td>
</tr>
</tbody>
</table>

4 weeks of treatment:
- 63% wound size reduction in Granulox® group with 5 patients fully healed
- 26% wound size reduction in Standard Care group with 1 patient fully healed

Healing speed: >100%

Wound size reduction in patients with diabetic foot ulceration receiving Standard of Care + Granulox® compared to retrospective control cohort with SoC alone (20/20 patients).

2) Pain scores in chronic wound patients

Average reported pain score (10 cm VAS)

<table>
<thead>
<tr>
<th>Week</th>
<th>Control</th>
<th>Haemoglobin spray</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>3.2</td>
<td>4.4</td>
</tr>
<tr>
<td>4</td>
<td>4.4</td>
<td>2.9</td>
</tr>
<tr>
<td>8</td>
<td>3.7</td>
<td>3.2</td>
</tr>
<tr>
<td>12</td>
<td>2.9</td>
<td>1.3</td>
</tr>
<tr>
<td>16</td>
<td>0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>20</td>
<td>0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>24</td>
<td>0.2</td>
<td>0.2</td>
</tr>
</tbody>
</table>

4 weeks of treatment:
- 85% of wound pain reduction in Granulox® group
- 13% of wound pain reduction in Standard Care group

> 70% advantage over Standard Care treatment

Pain reduction in patients with chronic wounds receiving Standard of Care + Granulox® compared to retrospective control cohort with SoC alone (50/50 patients).

3) Slough coverage in wounds

Mean wound slough coverage (baseline to week 26)

<table>
<thead>
<tr>
<th>Week</th>
<th>Control</th>
<th>Haemoglobin spray</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1%</td>
<td>11%</td>
</tr>
<tr>
<td>4</td>
<td>11%</td>
<td>17%</td>
</tr>
<tr>
<td>8</td>
<td>17%</td>
<td>17%</td>
</tr>
<tr>
<td>12</td>
<td>17%</td>
<td>17%</td>
</tr>
<tr>
<td>16</td>
<td>17%</td>
<td>17%</td>
</tr>
<tr>
<td>20</td>
<td>17%</td>
<td>17%</td>
</tr>
<tr>
<td>24</td>
<td>17%</td>
<td>17%</td>
</tr>
<tr>
<td>26</td>
<td>17%</td>
<td>17%</td>
</tr>
</tbody>
</table>

4 weeks of treatment:
- 99% wound slough reduction in Granulox® group
- 33% wound slough reduction in Standard Care group

66% advantage over Standard Care treatment

Slough reduction in patients with sloughy wounds receiving Standard of Care + Granulox® compared to retrospective control cohort with SoC alone (100/100 patients).
Diabetic foot ulcer
- 85 year old male patient
- Interdigital DI-II left.
- Diabetes mellitus
- pAOD
- Arterial Hypertension
- Wound persisted for 7 months
- Treatment with: Iruxol paste, Alginate, Hydrocoloid, Polyurethan foam

End of treatment after 73 days & 24 changes of bandages
(Granulox® applied with every change)

Venous leg ulcer
- 43 years old male patient
- Wound existed for 8 years, several relapses
- Budd-Chiari syndrome
- Portal hypertension
- Media sclerosis
- Start of Granulox® application: March 2012
- Successful end of therapy: June 2012

Wound closure after 16 weeks of treatment
(Granulox® applied every third day)

Arterial leg ulcer
- 85 year old female patient
- pAOD grade II–III
- Stenosis of A carotis interna (right)
- Multiple allergies
- Wound since 7 years

End of treatment after 169 days & 50 changes of bandages
(Granulox® applied with every change)
Cost saving with Granulox®

Faster healing saves costs

Many diabetic foot ulcers (DFU) do not respond well to wound healing treatments and cause substantial burden to healthcare resources, they often create a significant hardship for patients. When applied in addition to the standard wound care, the topical application of the haemoglobin spray Granulox® results in an acceleration of wound healing and an improvement in wound closure even in stalling wounds. To illustrate the impact of Granulox® on total treatment cost of DFU wounds from the perspective of the German statutory health insurance, the below investigation has been undertaken: a cohort of 20 patients with chronic DFU in an acute clinical setting and treated with Granulox® was compared to a cohort of 20 patients selected from the same period of the previous year using the same protocol, retrospectively, from the same clinic.

In the above cited investigation Granulox® demonstrated treatment costs in diabetic foot ulcers at least 40% lower than with standard of care.4

Fig.: Costs of standard wound care in comparison to standard wound care plus haemoglobin spray (Granulox®) in DFU patients.

Patients with standard wound care regimen caused an average total costs during 28 weeks of € 1,739, patients with adjunct topical haemoglobin contact spray (Granulox®) resulted in a total of € 1,020. The costs for therapeutic nursing care were the main cost component and amounted to € 848 for standard wound management versus € 475 for the treatment strategy in the Granulox®-group (= -44%). No amputation cost occurred in the Granulox® group.5
Granulox® is easy to handle and to apply

The application of Granulox® can be adjusted to the frequency of changing the corresponding wound dressing.

Apply Granulox® every time the dressing is changed, at least every 3 days.

1. Wound debridement and irrigation. Especially recommended HOCl /NaOCl products (e.g. Granudacyn).
2. Thin and even application of Granulox® from 5–10cm distance. 1 spray for 1 second covers a wound of 2x3cm.
3. Covering the wound with a breathable wound dressing.

Granulox®:

- Is an innovative medical device for the treatment of chronic wounds, such as venous leg ulcer, arterial leg ulcer, mixed leg ulcer, diabetic foot ulcers, secondary healing of surgical wounds and pressure sores. Can also be used on sloughy and infected wounds.
- Provides the wound with oxygen by means of diffusion. The active substance haemoglobin supplies the base of the wound externally with oxygen. The improved oxygen supply to the base of the wound supports wound healing.
Proving it every day

At Mölnlycke®, we deliver innovative solutions for managing wounds, improving surgical safety and efficiency and preventing pressure ulcers. Solutions that help achieve better outcomes and are backed by clinical and health-economic evidence.

In everything we do, we are guided by a single purpose: to help healthcare professionals perform at their best. And we’re committed to proving it every day.

References: